CIBC Bancorp USA’s Arcutis Biotherapeutics ARQT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$531K Buy
20,113
+5,354
+36% +$140K ﹤0.01% 1338
2026
Q2
$387K Buy
14,759
+783
+6% +$18.2K ﹤0.01% 1402
2026
Q1
$329K Buy
+13,976
New +$357K ﹤0.01% 1371
2025
Q3
$215K Buy
+11,417
New +$180K ﹤0.01% 1225

Other funds holding ARQT

CIBC Bancorp USA's ARQT Position: Q3 2026 in Review

CIBC Bancorp USA increased its Arcutis Biotherapeutics (ARQT) stake by 36% in Q3 2026, buying an estimated $140K and bringing the position to 20,113 shares worth $531K. The position accounts for ﹤0.01% of the portfolio, ranked #1338.

CIBC Bancorp USA first reported a position in ARQT in Q3 2025 and has held it in 4 quarters since. 294 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • CIBC Bancorp USA held 20,113 shares of Arcutis Biotherapeutics worth $531K as of Q3 2026.
  • CIBC Bancorp USA bought 5,354 Arcutis Biotherapeutics shares in Q3 2026, an estimated $140K.
  • Arcutis Biotherapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #1338 holding.
  • CIBC Bancorp USA first reported a position in Arcutis Biotherapeutics in Q3 2025 and has held it in 4 quarters since.
  • 294 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.